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Abstract 
In this study the in vitro activities of seven antibiotics (ciprofloxacin, ceftazidime, tetracycline, 
trimethoprim, sulfamethoxazole, polymyxin B and piperacillin) and six phytochemicals 
(protocatechuic acid, gallic acid, ellagic acid, rutin, berberine and myricetin) against five P. 
aeruginosa isolates, alone and in combination are evaluated. All the phytochemicals under 
investigation demonstrate potential inhibitory activity against P. aeruginosa. The combinations 
of sulfamethoxazole plus protocatechuic acid, sulfamethoxazole plus ellagic acid, sulfame-
thoxazole plus gallic acid and tetracycline plus gallic acid show synergistic mode of interaction. 
However, the combinations of sulfamethoxazole plus myricetin shows synergism for three 
strains (PA01, DB5218 and DR3062). The synergistic combinations are further evaluated for 
their bactericidal activity against P. aeruginosa ATCC strain using time-kill method. 
Sub-inhibitory dose responses of antibiotics and phytochemicals individually and in combina-
tion are presented along with their interaction network to suggest on the mechanism of ac-
tion and potential targets for the phytochemicals under investigation. The identified syner-
gistic combinations can be of potent therapeutic value against P. aeruginosa infections. These 
findings have potential implications in delaying the development of resistance as the anti-
bacterial effect is achieved with lower concentrations of both drugs (antibiotics and phyto-
chemicals). 
Key words: Synergy, combination therapy, phytochemicals, drug resistance. 
Introduction 
Pseudomonas aeruginosa is a major nosocomial 
pathogen, particularly dangerous to cystic fibrosis 
patients and populations having weak immune sys-
tem. Moreover, this organism is resistant to many 
antibacterial drugs [1]. Several mechanisms for resis-
tance against antibiotics have been proposed - which 
include antibiotic inactivation by enzymatic action, 
altering the efflux pump mechanisms, target muta-
tion, and decreased uptake of antibiotics [2]. Due to 
the frequent development of resistance during mo-
notherapy treatment of infected patients, multiple 
combinations of antibacterial agents are proposed 
[3-4]. Synergy is reported for β-lactams in combina-
tion with aminoglycoside antibiotics. However, the 
increasing resistance of Pseudomonas sp. to β-lactams 
and the toxicity concerns with the aminoglycosides 
limit the use of these combinations [5]. It is also re-
ported that polymyxin B can be used in combination 
Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
557 
with other antimicrobials to treat multidrug resistant 
(MDR) gram-negative respiratory tract infections 
caused by several clinical strains of P. aeruginosa [6]. 
Also, fluoroquinolones in combination with potent 
anti-pseudomonal β-lactam agents are reported to 
prevent the development of resistance in P. aeruginosa 
[7-8]. Earlier, Marie et al. reported that cystic fibrosis 
patients infected with P. aeruginosa can be effectively 
treated with clarithromycin/tobramycin combination 
[9]. However, alarmingly numbers of P. aeruginosa 
strains are reported to show resistance to multiple 
antibiotics. Concomitantly, multidrug resistance and 
dual resistance are major issues in developing a de-
finitive therapy for P. aeruginosa infections [10]. 
Since long, natural products are in use for the 
development of novel drugs to treat various bacterial 
infections. Several studies have proposed that natural 
compounds in combination with antibiotics are a new 
strategy for developing therapies for infections caused 
by bacterial species and that natural plant products 
can potentiate the activity of antibiotics in combina-
tion [10-13]. For example, secondary metabolites like 
essential oils, flavonols and alkaloids have been re-
ported to have antimicrobial properties [14-18]. Also, 
Michael and colleagues reported that the use of bac-
terial resistance modifiers such as efflux pump inhi-
bitors, derived from natural sources mainly from 
plants can suppress the emergence of MDR strains 
[19].  
Phenolic compounds from medicinal herbs and 
dietary plants possess a range of bioactivities like - 
antibacterial, antifungal, antiviral, antimutagenic and 
anti-inflammatory activities. Moreover, extensive 
clinical evidence has shown that chemoprevention by 
phenolic phytochemicals is an inexpensive, readily 
applicable approach in the chemotherapy and man-
agement [20]. Here, we investigate the in vitro anti-
microbial activities of 7 different antibiotics (ciprof-
loxacin, ceftazidime, tetracycline, trimethoprim, sul-
famethoxazole, polymyxin B and piperacillin) in 
combination with 6 phytochemicals (protocatechuic 
acid, gallic acid, ellagic acid, rutin, berberine and my-
ricetin) against 5 strains of P. aeruginosa using mini-
mum inhibitory concentrations (MIC), checkerboard 
test, and time-kill assay. All antibiotics under inves-
tigation have earlier been reported as an-
ti-pseudomonal drugs and have been reported to 
have different mechanisms of action (have different 
targets). The results of our analysis with data on anti-
biotic-phytochemical interaction network are pre-
sented. 
Materials and Methods 
Antimicrobial agents: 
Standard powders of antibiotics and phyto-
chemicals listed in Table 1 were obtained from Sigma 
- Aldrich, Singapore. Stock solutions were prepared 
and diluted according to Clinical and Laboratory 
Standards Institute (CLSI) standards and manufac-
turer's recommendations and stored at -20°C. 
Bacterial isolates: 
Five P. aeruginosa strains were used in this study 
including two clinical isolates (DB5218, DR3062) 
which was obtained from Singapore General Hospit-
al, Singapore. The other three strains were P. aerugi-
nosa ATCC 15692 (American Type Culture Collection, 
Manassas, USA), P. aeruginosa PA01 (University of 
Geneva, Switzerland), P. aeruginosa PT121 (University 
of Geneva, Switzerland). Before use, bacterial sus-
pension was made from fresh culture and stored at 
-80⁰C using 30% glycerol.  
Antimicrobial susceptibility testing: 
MIC is defined as the lowest concentration of the 
antimicrobial agent that inhibits the bacterial growth 
as detected by lack of visual turbidity. Broth micro-
dilution method was used to determine the MICs for 7 
antibiotics and 6 phytochemicals according to Clinical 
and Laboratory Standards Institute guidelines [21]. 
The medium used for the broth microdilution test was 
Iso-sensitest Broth (ISB). For each strain of P. aerugi-
nosa, three to five colonies were transferred from 
overnight growth plate into 5 ml of ISB to approx-
imate the density of 0.5 McFarland standard and in-
cubated at 35⁰C for 2-3 h. This suspension with the 
inoculum concentration of 108 colony forming units 
(CFU/ml) was then diluted to 106 CFU/ml with the 
Iso-sensitest broth. Serial two-fold dilutions of all the 
antimicrobial agents with the following concentra-
tions (µg/ml): ciprofloxacin (0.06 - 32), ceftazidime 
(0.25 - 32), trimethoprim (4 - 128), sulfamethoxazole (8 
- 512), tetracycline (4 - 128), polymyxinpolymyxin B 
(0.25 - 32), piperacillin (0.25 - 32), protocatechuic acid 
(250 - 8000), ellagic acid (1000 - 16000), gallic acid (250- 
8000), rutin (1000 - 16000), berberine (1000-16000), 
myricetin (100 - 1000) were prepared with ISB and 
placed in 96-well microtiter plates and the lowest 
concentration inhibiting visible growth after 18-20 h at 
35⁰C was recorded as MIC. 
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Table 1: List of antibiotics and phytochemicals used in this study 
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Checkerboard assay: 
The activity of phytochemicals and antibiotics in 
combination was investigated using the checkerboard 
broth microdilution method. Two fold serial dilutions 
of the antibiotic and two fold serial dilutions of the 
phytochemicals were prepared for every combination 
tested and 50 µl aliquots of each component was 
placed into the wells of the sterile 96-well microtiter 
plate. The inoculum was prepared using the above 
described MIC determination method. The microtiter 
plates were then incubated at 35⁰C and MIC was de-
termined after 18-20 h of incubation.  
The Fractional inhibitory concentration (FIC in-
dex) for all the combinations was determined using 
the following formula, 
FIC index = FICA + FICB = [A]/MICA + [B]/MICB 
FICA, FICB – Fractional inhibitory concentration 
of drug A & B respectively.  
MICA, MICB – Minimum inhibitory concentration of 
drug A & B respectively. 
[A], [B] – Concentration of drug A & B respec-
tively. 
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FIC index by checkerboard method is inter-
preted as follows: ≤ 0.5- synergy; > 0.5 and ≤ 4- addi-
tivity; and > 4 - antagonism. 
The effects of sub-inhibitory concentrations of 
test compounds individually and in combination on 
PA01 growth were also evaluated by measuring the 
growth rates after 20 h of incubation at 35⁰C in mi-
crotitre plates and OD600 was measured. 
Time-kill assay: 
Time-kill assays were performed using the iden-
tified synergistic combinations (SMX plus PA, SMX 
plus EA, SMX plus GA and TET plus GA) against a 
single bacterial isolate (ATCC 15692). Individual co-
lonies were isolated from the overnight growth plate 
and suspended in sterile ISB to approximate the den-
sity of 0.5 McFarland standard. The suspension was 
diluted 1:10 in ISB to obtain a standard inoculum of 1 
x 106 CFU/ml. 100 µl of the diluted suspension was 
added to 0.9 ml of ISB. Double dilutions for each an-
tibiotic and phytochemicals were prepared. Tubes 
containing individual drugs and the combination 
were incubated at 35°C for 24 h. From each tube 100 µl 
of sample was removed at 0, 4, 8 and 24 h, respec-
tively and plated to count the viable cells. Growth 
control and sterility control were included for each 
assay. The killing rate was determined by plotting 
viable colony counts (CFU/ml) against time. Synergy 
was defined as a ≥2 log10 CFU/ml decrease of viable 
count by the combination compared with the most 
active single agent. 
Statistical analysis: 
The dose response values and time-kill data are 
presented as mean ± SD (Standard deviation). The 
analysis was performed in triplicate.  
Results 
Antimicrobial susceptibility testing: 
This study explored the antimicrobial activities 
of the phytochemicals alone and in combination with 
7 anti-pseudomonal drugs (antibiotics) against 5 
strains of P. aeruginosa (including 2 clinical strains). 
All the 5 strains of P. aeruginosa were susceptible to the 
anti-pseudomonal drugs chosen for investigation i.e. 
ciprofloxacin, ceftazidime, trimethoprim, sulfame-
thoxazole, tetracycline, polymyxin B and piperacillin. 
MIC value was found to be highest for sulfamethox-
azole (128µg/ml) and lowest for ciprofloxacin 
(0.125µg/ml) among the antibiotics (Table 2).  
The phytochemicals used in this study signifi-
cantly inhibited the growth of all the bacterial strains 
under investigation. Among the phytochemicals 
tested, myricetin (500µg/ml), protocatechuic acid 
(2000µg/ml) and gallic acid (2000µg/ml) showed 
lower MIC than ellagic acid (4000µg/ml), rutin 
(4000µg/ml) and berberine (4000µg/ml). The mini-
mum inhibitory concentrations of the phytochemicals 
are listed in Table 2. 
 
Table 2: Antimicrobial activity (MIC values) of all the an-
tibiotics and phytochemicals against five strains of P. aeru-
ginosa 
Antimicrobials Minimum inhibitory concentration (µg/ml) 
P. aeruginosa strains 
ATCC PA01 PT121 DB5218 
 
DR3062 
Ciprofloxacin 0.125 0.125 0.125 0.125 0.25 
Ceftazidime 2 2 2 4 8 
Trimethoprim 32 32 32 32 32 
Sulfamethoxazole 128 128 128 128 128 
Tetracycline 32 32 32 32 32 
Polymyxin B 2 2 2 2 2 
Piperacillin 2 2 2 2 16 
Protocatechuic acid 2000 2000 2000 2000 2000 
Ellagic acid 4000 4000 4000 4000 4000 
Gallic acid 2000 2000 2000 2000 2000 
Rutin 4000 4000 4000 4000 4000 
Berberine 4000 4000 4000 4000 4000 
Myricetin 500 500 500 500 500 
 
 
Combination of phytochemicals and antibiotics against P. 
aeruginosa: 
The combination effects of anti-pseudomonal 
drugs and phytochemicals are summarized in Table 3.  
Our results show that the combinations of sul-
famethoxazole plus protocatechuic acid, sulfame-
thoxazole plus ellagic acid and sulfamethoxazole plus 
gallic acid have synergistic mode of interactions for all 
the strains of P. aeruginosa under investigation. It was 
also observed that the antifolate drug, sulfamethox-
azole is synergistic with myricetin in three strains 
(PA01, DB5218 and DR3062) and additive for two 
strains (ATCC and PT121) of P. aeruginosa. Also, te-
tracycline in combination with gallic acid demon-
strates synergy for all the isolates under investigation. 
Other antimicrobials – ciprofloxacin, ceftazidime, 
trimethoprim, polymyxin B and piperacillin show 
additivity in combination with phytochemicals, for all 
the strains under investigation. It is noteworthy, that 
none of the antibiotic -phytochemical combinations 
show antagonism.  
The FIC indices of the combinations sulfame-
thoxazole plus protocatechuic acid and sulfamethox-
azole plus ellagic acid range from 0.25 – 0.5, showing 
significant synergistic activity for all the strains under 
investigation (Table 3). 
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Table 3: In vitro activity of all antimicrobial combinations against five strains of P. aeruginosa. The values show the FIC index. 
Antibiotics + 
Phytochemicals 
Combination 
P. aeruginosa strains 
ATCC PA01 PT121 DB5218 DR3062 
Checkerboard FIC index (Interpretation) 
      
CIP+PA 2(I) 2(I) 2(I) 2(I) 1(I) 
CIP+EA 2(I) 2(I) 2(I) 2(I) 1(I) 
CIP+GA 2(I) 2(I) 2(I) 2(I) 1(I) 
CIP+RUT 1(I) 1(I) 1(I) 1(I) 1(I) 
CIP+BER 2(I) 2(I) 2(I) 2(I) 1(I) 
CIP+MYR 2(I) 2(I) 2(I) 2(I) 2(I) 
      
CF+PA 1(I) 1(I) 1(I) 1(I) 1(I) 
CF+EA 1(I) 1(I) 1(I) 2(I) 1(I) 
CF+GA 1(I) 1(I) 1(I) 2(I) 1(I) 
CF+RUT 1(I) 1(I) 1(I) 1(I) 2(I) 
CF+BER 1(I) 1(I) 1(I) 1(I) 2(I) 
CF+MYR 1(I) 1(I) 1(I) 1(I) 2(I) 
      
TMP+PA 1(I) 1(I) 1(I) 1(I) 1(I) 
TMP +EA 1(I) 1(I) 1(I) 1(I) 1(I) 
TMP +GA 1(I) 1(I) 1(I) 1(I) 1(I) 
TMP +RUT 2(I) 2(I) 2(I) 2(I) 2(I) 
TMP +BER 2(I) 2(I) 2(I) 2(I) 2(I) 
TMP +MYR 2(I) 2(I) 2(I) 2(I) 2(I) 
      
SMX+PA 0.5(S) 0.25(S) 0.25(S) 0.25(S) 0.25(S) 
SMX +EA 0.5(S) 0.25(S) 0.25(S) 0.25(S) 0.25(S) 
SMX +GA 0.5(S) 0.5(S) 0.5(S) 0.5(S) 0.5(S) 
SMX +RUT 1(I) 1(I) 1(I) 1(I) 1(I) 
SMX +BER 1(I) 1(I) 1(I) 1(I) 1(I) 
SMX +MYR 1(I) 0.5(S) 1(I) 0.5(S) 0.5(S) 
      
TET+PA 1(I) 1(I) 1(I) 1(I) 1(I) 
TET +EA 1(I) 1(I) 1(I) 1(I) 1(I) 
TET +GA 0.5(S) 0.5(S) 0.5(S) 0.5(S) 0.5(S) 
TET +RUT 1(I) 1(I) 1(I) 1(I) 1(I) 
TET +BER 1(I) 1(I) 1(I) 1(I) 1(I) 
TET +MYR 1(I) 1(I) 1(I) 1(I) 1(I) 
      
POL B+PA 2(I) 2(I) 2(I) 2(I) 2(I) 
POL B +EA 2(I) 2(I) 2(I) 2(I) 2(I) 
POL B +GA 2(I) 2(I) 2(I) 2(I) 2(I) 
POL B +RUT 2(I) 2(I) 2(I) 2(I) 2(I) 
POL B +BER 2(I) 2(I) 2(I) 2(I) 2(I) 
POL B +MYR 4(I) 4(I) 4(I) 4(I) 4(I) 
      
PIP+PA 1(I) 1(I) 1(I) 1(I) 1(I) 
PIP+EA 2(I) 2(I) 2(I) 2(I) 1(I) 
PIP+GA 1(I) 1(I) 1(I) 1(I) 1(I) 
PIP+RUT 2(I) 2(I) 2(I) 2(I) 2(I) 
PIP+BER 1(I) 1(I) 1(I) 1(I) 2(I) 
PIP+MYR 2(I) 2(I) 2(I) 2(I) 4(I) 
S = Synergistic; I = Additivity/Indifferent. 
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The growth inhibitory properties of all the test 
compounds and additive combinations assayed over 
20 h period in microtiter wells at sub-inhibitory con-
centration was similar to the growth control well (no 
antimicrobials). Moreover, the synergistic combina-
tions were found to inhibit the test strain (PA01) 
growth at similar concentrations (Figure 1). The drug 
interaction data between various classes of antibiotics 
and phytochemicals is represented as a figure to pro-
vide some insights on their mechanism of action 
(Figure 2).  
 
 
 
 
 
Fig. 1: PA01 growth in subminimum inhibitory concentrations of individual antibiotics and phytochemicals and their 
combination. Dose response and classification of interactions for antibiotics and phytochemicals used in this study. Each 
panel consists of bars representing measured growth rates (OD600 nm) after 24 hr incubation with sub-inhibitory concen-
tration of the antimicrobials, from left to right: growth control (no antibiotics), antibiotics alone (1/4 x MIC), phytochemicals 
alone (1/4 x MIC), antibiotics + phytochemicals (1/4 + 1/4 x MIC). The background colour represents the type of interac-
tions, red – additive/indifferent, green – synergistic. 
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Fig. 2: Network interactions between antibiotics and phytochemicals. Antibiotics are classified based on their respective 
targets and mechanism of action. CE, ceftazidime; PI, piperacillin - cell wall inhibitors; T, trimethoprim; S, sulfamethoxazole 
– folic acid biosynthesis inhibitors; POL B, polymyxin B – cell membrane inhibitors; TET, tetracycline – 30S ribosome 
inhibitors; CIP, ciprofloxacin – DNA gyrase and toposiomerase IV inhibitors. Phytochemicals are classified based on their 
classes. PA, protocatechuic acid; GA, gallic acid; EA, ellagic acid –polyphenol antioxidants (phenolic acids); BER, berberine – 
alkaloid; RUT, rutin; MYR, myricetin – flavonoids. 
 
Time-kill curves: 
Time-kill assays for the most potent synergistic 
combinations (sulfamethoxazole plus protocatechuic 
acid, sulfamethoxazole plus ellagic acid, sulfame-
thoxazole plus gallic acid and tetracycline plus gallic 
acid) on ATCC strain are shown (Figures 3: A-D). The 
net reduction in colony count was seen consistently 
(throughout 24 h) at (1/2th + 1/2th) x MIC for the 
identified synergistic drug-herb combinations. Any 
single active agent alone at 1/2th x MIC did not show 
significant inhibition of the isolates tested. The rate of 
killing was higher at 8 h with maximum reduction in 
the colony count at 24 h. When 1/2th x MIC sulfame-
thoxazole was combined with 1/2th x MIC protoca-
techuic acid, 1/2th x MIC sulfamethoxazole was com-
bined with 1/2th x MIC gallic acid, 1/2th x MIC tetra-
cycline was combined with 1/2th x MIC gallic acid, 
significant decrease in bacterial count was observed 
between 8 – 24 h with maximum reduction in the 
growth baseline by 4 – 5 log10 CFU/ml. However, 
when 1/2th x MIC sulfamethoxazole was combined 
with 1/2th x MIC ellagic acid a reduction of 1 - 2 log10 
decrease in viable count occurred at 24 h.  
Discussion 
P. aeruginosa is a tenacious pathogen because of 
its ability to develop resistance to multiple antibiotics. 
Though, there are a few anti-pseudomonal drugs in 
the pipeline [22], there is an urgent need for novel and 
effective infection control strategy to face this highly 
critical therapeutic challenge of drug resistance 
[23-24]. 
Since long, bioactive compounds from natural 
sources have shown the potential to inhibit resistance 
mechanisms [25]. Here, we report on the synergistic 
and additive interactions between selected phyto-
chemicals and antibiotics which are folate biosynthe-
sis inhibitors, DNA/protein synthesis inhibitors, and 
cell permeability/cell wall inhibitors.  
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Antibiotics and phytochemicals - interaction analysis  
Folate Biosynthesis inhibitors: 
Sulfamethoxazole (a sulfonamide), competitive-
ly inhibits the binding of para aminobenzoic acid 
(pABA) to the enzyme dihydropteroate synthase 
(DHPS) that catalyses the formation of dihydrofolate 
[26]. Trimethoprim inhibits dihydrofolate reductase 
(DHFR) enzyme which catalyses the 
NADPH-dependent reduction of dihydrofolate to 
tetrahydrofolate, an important cofactor involved in 
supplying one carbon for the synthesis of purines, 
pyrimidines, methionine and many other amino ac-
ids. It must be mentioned that nearly all prokaryotes 
must synthesize folate compounds de novo, starting 
with GTP and utilizing several different enzymes in a 
multi-step pathway, whereas eukaryotes (including 
human) are able to utilize the dietary folates by up-
take through a carrier-mediated transport system [27]. 
Hence, DHFR and DHPS are good targets for antifo-
lates [28]. 
Recently, we proposed that phytochemicals 
(protocatechuic acid, gallic acid, quercetin and myri-
cetin) possibly bind to P. aeruginosa DHFR and in 
combination with sulfamethoxazole may inhibit dif-
ferent steps in the same pathway, thereby resulting in 
synergistic mode of action. On the other hand indif-
ferent/additive interaction of trimethoprim and 
phytochemicals may be due to the binding of these 
phytochemicals into the active site cavity of DHFR, 
thereby resulting in interactions with common target 
residues similar to that of trimethoprim, leading to 
competitive inhibition and no inhibition of cell 
growth [29]. Here, we reconfirm the above findings 
using 5 strains - including two clinical strains- of P. 
aerugoinosa and also provide data on MICs, and 
time-kill. We further report on synergism between the 
combination of ellagic acid and sulfamethoxazole and 
propose similar mode of action, as ellagic acid may 
also potentially bind in P. aeruginosa DHFR active 
site.However, combinations of sulfamethoxazole plus 
rutin, sulfamethoxazole plus berberine, trimethoprim 
plus rutin and trimethoprim plus berberine resulted 
in indifferent/additive mode of interaction.  
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Figure 3: Time-kill data for synergistic combinations at ½ x MIC against P. aeruginosa ATCC strain 15692. (A) Combinations 
of sulfamethoxazole (SMX) and protocatechuic acid (PA); (B) Combinations of sulfamethoxazole (SMX) and gallic acid (GA); 
(C) Combinations of sulfamethoxazole (SMX) and ellagic acid (EA); (D) Combinations of tetracycline (TET) and gallic acid 
(GA). Filled diamond, control; Filled square, antibiotics; Filled triangle, phytochemicals; Filled circle, antibiotic and phyto-
chemical combination. 
 
 
Protein synthesis (30S ribosome) inhibitor: 
Synergistic interactions were observed for com-
bination of tetracycline and gallic acid for all the P. 
aeruginosa strains under investigation. Sudano et al., 
reported that epigallocatechin gallate enhances the 
tetracycline activity for resistant staphylococcal iso-
lates by impairment of tetracycline efflux pump ac-
tivity and increased intracellular retention of the drug 
leading to synergistic drug combination [30]. Since, 
gallic acid is a structural component of epigallocate-
chin galate, there is a possibility that it may behave 
similarly in combination with tetracycline. Additive 
mode of interactions was observed for combinations 
of tetracycline and protocatechuic acid, ellagic acid, 
rutin, berberine and myricetin for all the P. aeruginosa 
strains under investigation.  
DNA replication inhibitor: 
The combinations of ciprofloxacin/ 
phytochemicals were found to be additive. Ciprof-
loxacin has been earlier reported to have two targets 
(DNA gyrase and DNA topoisomerase IV) [31]. It is 
suggested that quercetin, inhibits supercoiling activity 
of E. coli bacterial gyrase by binding to the ATP 
binding site of gyrase B [32]. It is also reported that 
quercetin and myricetin bind to DNA and induce 
enzymic DNA breakage [33]. Recently, epigallocate-
chin gallate is reported to inhibit E. coli bacterial DNA 
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gyrase [34]. Bernard et al. found that rutin induces 
topoisomerase IV-mediated DNA cleavage and 
growth inhibition in E. coli [35]. The mechanism of 
action of berberine was found to be similar to that of 
rifampicin and norfloxacin possibly targeting RNA 
polymerase, DNA gyrase and topoisomerase IV en-
zymes [36]. The present study interaction data from 
(Figure 2) shows similar mechanism of action of the 
above phytochemicals as DNA synthesis inhibitors by 
having indifferent activity in combination with ci-
profloxacin. 
Cell wall / cell membrane permeability inhibitors: 
Ceftazidime, causes cell lysis in P. aeruginosa due 
to its primary activity against membrane proteins to 
which penicillin is reported to bind [37]. Also, quer-
cetin is reported to cause increase in permeability of 
the inner bacterial membrane and loss of membrane 
potential [38]. On the other hand, galangin, a struc-
tural analogue of quercetin, induces cytoplasmic 
membrane interference damage and potassium lea-
kage leading to cell wall damage [39]. The correlation 
between indifferent activities of phytochemicals in 
combination with ceftazidime from the experimental 
data may possibly suggest that these compounds may 
act at same target either at different sites in the cy-
toplasmic membrane with direct contact with agonist 
site or at the same site. 
Polymyxin B is reported to have a detergent like 
mechanism of action and interacts with lipoplysac-
charide (LPS) of the outer membrane of P. aeruginosa 
[40-41]. Polymyxin B in combination with the tested 
phytochemicals results in additive/indifferent mode 
of interaction. The LPS molecules in the outer leaflet 
form specific contacts with integral outer membrane 
proteins and are required for LPS transport to the 
bacterial cell surface [42]. It is earlier suggested that in 
the presence of lipopolysaccharide as a barrier in 
gram-negative bacteria, the susceptibility of catechins 
may be low [43]. The combinations of polymyxin B 
plus phytochemicals may help overcome this barrier 
due to the detergent like activity of polymyxin B and 
cytoplasmic membrane damage inducing ability of 
phytochemicals. However, it is possible that there 
may be a direct competition for binding to LPS or by 
indirectly affecting the same site of the same target by 
overlapping actions subsequently resulting in addi-
tive mode of action. Similarly, piperacillin, an extened 
spectrum β-lactam antibiotic shows additive effect in 
combination with the phytochemicals under investi-
gation. 
This study highlights the various systemic inte-
raction patterns and may help identify new drug 
combinations with novel mechanism of action. It must 
be noted that no antagonistic interaction was ob-
served for any antibiotic- phytochemical combination 
studied. These results suggest that the identified 
combinations could be potential and effective strate-
gy, without the concern of antagonistic interactions. 
One of the major concerns for the dietary phyto-
chemicals under investigation is the higher MIC val-
ues in comparison to antibiotics, which are generally 
in the range of < 10 µg/ml range [44]. However, it is 
noteworthy that, the main polyphenol dietary sources 
are fruits and beverages with an average total intake 
of 1g/day and after the consumption of 10-100 mg of 
a single phenolic compound, the maximum concen-
tration in plasma rarely exceeds 1 µM [45]. Addition-
ally the toxicity of these phytochemicals are very low 
and as of date, very few adverse side effects are re-
ported [46]. Nonetheless, detailed analysis needs to be 
carried out to characterize the interactions of antibac-
terial phytochemicals and antibiotics with the use of 
different approaches and methods facilitated by tar-
gets profile and toxicity data.  
Conclusion 
The present study clearly highlights the low 
toxic potential of phytochemicals as antibacterial 
compounds and suggest on the possibility of use of 
the above shown synergistic drug-herb combinations 
for combating infections caused by this pathogen. The 
drug-herb network presented in this study shows the 
level of interactions between various classes of anti-
biotics and phytochemicals and provides a baseline to 
identify the potential mechanism of action of these 
potential phytochemicals. Moreover, phytochemicals 
are reported to have the capability of increasing the 
susceptibility of the pathogen to various drugs and 
also reduce the toxicity of the drugs when used in 
combination. Finally, the experimental findings en-
courage further studies with these agents and other 
antimicrobial classes and in vivo animal experiments 
to validate these interesting observations before clin-
ical test can move forward. The investigations are 
underway to further characterize the interaction of the 
above phytochemicals and antibiotics. 
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34. Gradišar H, Pristovs ̌ek P, Plaper A, et al. Green tea catechins 
inhibit bacterial DNA gyrase by interaction with its ATP 
binding site. Journal of Medicinal Chemistry. 2007; 50: 264-271. 
35. Bernard FX, Sablé S, Cameron B, et al. Glycosylated flavones as 
selective inhibitors of topoisomerase IV. Antimicrobial Agents 
and Chemotherapy. 1997; 41: 992-998. 
36. Yi ZB, Yan Y, Liang YZ, et al. Evaluation of the antimicrobial 
mode of berberine by LC/ESI-MS combined with principal 
component analysis. Journal of Pharmaceutical and Biomedical 
Analysis. 2007; 44: 301-304. 
37. Hayes MV, Orr DC. Mode of action of ceftazidime: Affinity for 
the penicillin-binding proteins of Escherichia coli K12, 
Pseudomonas aeruginosa and Staphylococcus aureus. Journal 
of Antimicrobial Chemotherapy. 1983; 12: 119-126. 
Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
568 
38. Mirzoeva OK, Grishanin RN, Calder PC. Antimicrobial action 
of propolis and some of its components: The effects on growth, 
membrane potential and motility of bacteria. Microbiological 
Research. 1997; 152: 239-246. 
39. Cushnie TPT, Lamb AJ. Detection of galangin-induced 
cytoplasmic membrane damage in Staphylococcus aureus by 
measuring potassium loss. Journal of Ethnopharmacology. 
2005; 101: 243-248. 
40. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: 
Old antibiotics for emerging multiresistant gram-negative 
bacteria. Annals of Pharmacotherapy. 1999; 33: 960-967. 
41. Hancock REW. Peptide antibiotics. Lancet. 1997; 349: 418-422. 
42. Bos MP, Tommassen J. Biogenesis of the Gram-negative 
bacterial outer membrane. Current Opinion in Microbiology. 
2004; 7: 610-616. 
43. Ikigai H, Nakae T, Hara Y, et al. Bactericidal catechins damage 
the lipid bilayer. Biochimica et Biophysica Acta - 
Biomembranes. 1993; 1147: 132-136. 
44. Clinical and Laboratory Standards Institute. Performance 
Standards for Antimicrobial Susceptibility Testing: Twelfth In-
formational Supplement M100-S12. Wayne, PA: Clinical and 
Laboratory Standards Institute. 2002. 
45. Scalbert A, Williamson G. Dietary intake and bioavailability of 
polyphenols. Journal of Nutrition. 2000; 130: 2073S-2085S. 
46. Bode AM, Dong Z. Molecular and cellular targets. Mol 
Carcinog. 2006; 45: 422-430. 
47. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, 
applications, molecular biology, and epidemiology of bacterial 
resistance. Microbiology and Molecular Biology Reviews. 2001; 
65: 232-260. 
48. Iida K, Hirata S, Nakamuta S, et al. Inhibition of cell division of 
Escherichia coli by a new synthetic penicillin, piperacillin. 
Antimicrobial Agents and Chemotherapy. 1978; 14: 257-266. 
49. Mason TL, Bruce P W. Inactivation of red beet β-glucan 
synthase by native and oxidized phenolic compounds. 
Phytochemistry. 1987; 26: 2197-2202. 
50. Mori A, Nishino C, Enoki N, et al. Antibacterial activity and 
mode of action of plant flavonoids against Proteus vulgaris and 
Staphylococcus aureus. Phytochemistry. 1987; 26: 2231-2234. 
